EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY

metrics 2024

Unveiling Breakthroughs in Pharmacological Therapy

Introduction

EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, published by the American Psychological Association, stands as a pivotal resource within the fields of pharmacology and psychiatry. With an ISSN of 1064-1297 and an E-ISSN of 1936-2293, this journal contributes significantly to the understanding of psychopharmacological interventions through its rich array of research articles, reviews, and clinical studies. Classified within the Q2 category in both Pharmacology and Psychiatry and Mental Health, it reflects a solid standing in academic performance, evidenced by its rankings in Scopus, where it places within the top half of its categories. Spanning from 1993 to 2024, it seeks to provide an essential platform for the dissemination of knowledge and advancements that influence clinical practice and therapeutic approaches. Although not an open-access journal, its impact on the development of evidence-based psychopharmacological treatments cannot be overstated, making it a vital resource for researchers, clinically active professionals, and students eager to stay abreast of cutting-edge developments in mental health and pharmacology.

Metrics 2024

SCIMAGO Journal Rank0.83
Journal Impact Factor2.40
Journal Impact Factor (5 years)2.40
H-Index101
Journal IF Without Self2.40
Eigen Factor0.00
Normal Eigen Factor0.66
Influence0.82
Immediacy Index0.30
Cited Half Life8.70
Citing Half Life7.70
JCI0.78
Total Documents1492
WOS Total Citations3004
SCIMAGO Total Citations10632
SCIMAGO SELF Citations782
Scopus Journal Rank0.83
Cites / Document (2 Years)2.43
Cites / Document (3 Years)2.40
Cites / Document (4 Years)2.59

Metrics History

Rank 2024

Scopus

Psychiatry and Mental Health in Medicine
Rank #234/567
Percentile 58.73
Quartile Q2
Pharmacology (medical) in Medicine
Rank #118/272
Percentile 56.62
Quartile Q2
Pharmacology in Pharmacology, Toxicology and Pharmaceutics
Rank #168/313
Percentile 46.33
Quartile Q3

IF (Web Of Science)

PHARMACOLOGY & PHARMACY
Rank 188/354
Percentile 47.00
Quartile Q3
PSYCHIATRY
Rank 126/276
Percentile 54.50
Quartile Q2
PSYCHOLOGY, BIOLOGICAL
Rank 7/18
Percentile 63.90
Quartile Q2
PSYCHOLOGY, CLINICAL
Rank 65/180
Percentile 64.20
Quartile Q2

JCI (Web Of Science)

PHARMACOLOGY & PHARMACY
Rank 133/354
Percentile 62.43
Quartile Q2
PSYCHIATRY
Rank 112/276
Percentile 59.42
Quartile Q2
PSYCHOLOGY, BIOLOGICAL
Rank 7/18
Percentile 61.11
Quartile Q2
PSYCHOLOGY, CLINICAL
Rank 82/180
Percentile 54.44
Quartile Q2

Quartile History

Similar Journals

JOURNAL OF DRUG ISSUES

Championing Research for a Healthier Tomorrow
Publisher: SAGE PUBLICATIONS INCISSN: 0022-0426Frequency: 4 issues/year

JOURNAL OF DRUG ISSUES, published by SAGE PUBLICATIONS INC, serves as a pivotal platform for researchers and professionals dedicated to the multifaceted exploration of drug-related topics across various fields, including health, medicine, psychiatry, and public health. With an ISSN of 0022-0426 and an E-ISSN of 1945-1369, this esteemed journal has maintained a consistent output since its inception in 1971 and is set to continue its contributions through 2024. Reflecting its high academic standards, it has achieved a Q2 ranking in Health (Social Science) and Q3 rankings in several related categories, underscoring its relevance and influence among scholarly work. The journal is indexed in Scopus, with respectable rankings in various medical and health-related disciplines, highlighting its role as an essential resource for those invested in the vigorous discourse surrounding drug issues. Although not an open-access publication, the journal ensures that access to its extensive research findings remains available to a broad audience, solidifying its importance in advancing knowledge and informing best practices in the field.

Therapeutic Advances in Psychopharmacology

Driving Progress in Psychopharmacological Research
Publisher: SAGE PUBLICATIONS LTDISSN: 2045-1253Frequency: 1 issue/year

Therapeutic Advances in Psychopharmacology is a leading open-access journal published by SAGE Publications Ltd, focusing on the dynamic integration of pharmacological therapies and psychological health. Since its inception in 2011, this journal has made a significant impact on the fields of pharmacology and psychiatry, consistently earning a Q1 ranking in both categories as of 2023, reflecting its esteemed position within the scientific community. With an impressive Scopus rank placing it in the top 15% across relevant disciplines, the journal serves as a vital platform for researchers, professionals, and students eager to explore cutting-edge advancements in psychopharmacology. The open-access model, established in 2019, ensures that groundbreaking research is accessible to a wide audience, fostering collaboration and innovation in therapeutic strategies for mental health disorders. Through the dissemination of high-quality research and reviews, Therapeutic Advances in Psychopharmacology is committed to advancing understanding and practice within this critical field.

AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE

Championing Scholarly Discourse on Substance Abuse
Publisher: TAYLOR & FRANCIS INCISSN: 0095-2990Frequency: 6 issues/year

American Journal of Drug and Alcohol Abuse is a highly regarded publication in the field of substance abuse research, published by Taylor & Francis Inc. With its inception in 1974, this journal has become an essential resource for scholars and practitioners interested in clinical psychology, psychiatry, and the multifaceted issues surrounding drug and alcohol use. It holds a notable Q2 ranking in Clinical Psychology, Medicine (miscellaneous), and Psychiatry and Mental Health, emphasizing its impact and relevance in these domains. The journal's 2023 Scopus rankings further highlight its standing, placing it in the top quartile of publications with established readership and citation metrics. Researchers and students can benefit from its comprehensive articles that delve into the complexities of substance use, treatment methodologies, and the socio-psychological underpinnings of addiction. Whether you seek to access cutting-edge studies or contribute to ongoing discourse in the field, the American Journal of Drug and Alcohol Abuse serves as a vital hub for knowledge dissemination and scholarly engagement.

JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY

Advancing pediatric mental health through innovative research.
Publisher: MARY ANN LIEBERT, INCISSN: 1044-5463Frequency: 10 issues/year

JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, published by MARY ANN LIEBERT, INC, stands as a premier academic journal dedicated to advancing the field of pediatric psychopharmacology. With a rich history of publication spanning from 1990 to 2024, this journal presents cutting-edge research that informs clinical practices and policy decisions impacting the mental health of children and adolescents. Ranked in the Q2 category for both Pediatrics, Perinatology and Child Health and Pharmacology (medical) as of 2023, it reflects its critical contribution to these fields, along with a respectable Q3 status in Psychiatry and Mental Health. Researchers and practitioners benefit from the journal's rigorous peer-reviewed articles, which delve into the efficacy, safety, and ethical implications of pharmacological treatments tailored for young populations. Although the journal does not currently offer Open Access, it remains a vital resource for anyone engaged in child and adolescent health research and treatment strategies. Its commitment to fostering dialogue and innovation in psychopharmacology ensures its pivotal role in shaping future standards and practices in this essential area of medical science.

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Connecting global minds in pharmacology and psychiatry.
Publisher: OXFORD UNIV PRESSISSN: 1461-1457Frequency: 12 issues/year

The INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, published by OXFORD UNIV PRESS, is a leading open-access journal in the fields of pharmacology and psychiatry, with an impressive impact factor reflecting its prominence in academic research. Since its inception in 1998, the journal has provided a crucial platform for the publication of high-quality research, offering insights into the effects of neuropharmacological agents on mental health. As of 2023, it ranks in the Q1 category for both Pharmacology and Psychiatry & Mental Health, underscoring its relevance and authority within the scientific community. With notable rankings in various medical subspecialties, it attracts contributions that advance our understanding of psychiatric disorders and therapeutic strategies. The accessible nature of the journal, following its transition to open access in 2015, has expanded its reach, making knowledge and findings readily available to researchers, professionals, and students globally. This commitment to disseminating impactful research ensures the journal remains at the forefront of neuropsychopharmacological advancements.

ADDICTIVE BEHAVIORS

Exploring the Depths of Addiction Science
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0306-4603Frequency: 12 issues/year

ADDICTIVE BEHAVIORS is a prestigious journal published by PERGAMON-ELSEVIER SCIENCE LTD, specializing in the critical examination and exploration of addiction-related issues across diverse fields including Clinical Psychology, Psychiatry and Mental Health, and Toxicology. With a robust history dating back to 1975 and convergence extending to 2024, the journal is esteemed for its rigorous peer-reviewed research that contributes significantly to understanding addiction phenomena. Ranked in the Q1 category for its focus areas, it stands out within the academic community, evidenced by its impressive Scopus rankings—25th in Clinical Psychology and 14th in Toxicology—placing it in the top tier of its disciplines. This journal offers valuable insights into addiction behaviors, treatment methodologies, and public health implications, making it an essential resource for researchers, practitioners, and students seeking to advance their knowledge and impact the field. Although not Open Access, it provides vital access options for institutions and individuals invested in addiction studies.

Activitas Nervosa Superior Rediviva

Connecting Research and Practice in Mental Health
Publisher: SLOVAK ACAD SCIENCES, INST NORMAL & PATHOLOGICAL PHYSIOLOGYISSN: 1337-933XFrequency: 4 issues/year

Activitas Nervosa Superior Rediviva is a peer-reviewed journal dedicated to the fields of neuropsychology, physiological psychology, psychiatry, and mental health research. Published by the esteemed SLOVAK ACADEMY OF SCIENCES, INSTITUTE OF NORMAL AND PATHOLOGICAL PHYSIOLOGY, this journal embraces an open-access model, facilitating the dissemination of critical findings and discussions within these evolving fields. With a focus on innovative studies spanning from 2009 to 2024, it provides a vital platform for researchers and professionals seeking to understand the complexities of the nervous system and related disorders. Although currently classified in the fourth quartile across relevant categories including neuropsychology and psychiatric health, the journal’s commitment to publishing quality research contributes significantly to the ongoing discourse among academics and clinicians alike. Activitas Nervosa Superior Rediviva invites scholars to engage with its content and further strengthen the integration of research and practice in mental health and neurological sciences.

Journal of Mental Health and Human Behaviour

Bridging research and practice for impactful human behaviour change.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0971-8990Frequency: 2 issues/year

The Journal of Mental Health and Human Behaviour is a distinguished publication dedicated to advancing the field of mental health, focusing on innovative research and practical applications that enhance human behaviour and overall well-being. Published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, this journal has been an open-access platform since 2014, enabling wider dissemination of knowledge and fostering collaboration among researchers, professionals, and students globally. With an ISSN of 0971-8990 and E-ISSN 2543-1897, it aims to provide a comprehensive array of peer-reviewed articles that cover various facets of mental health, including psychological theories, therapeutic practices, and sociocultural influences. The journal plays an integral role in bridging the gap between research and practice, making it essential for those who are committed to improving mental health outcomes and advocating for human behaviour change. Published in India, the journal not only highlights regional issues but also contributes to international discussions on mental health trends and interventions, affirming its importance in a rapidly evolving field.

NEUROPSYCHOBIOLOGY

Advancing Knowledge: Bridging Gaps in Neuropsychological Research
Publisher: KARGERISSN: 0302-282XFrequency: 6 issues/year

NEUROPSYCHOBIOLOGY, published by KARGER, is a leading academic journal that has been at the forefront of exploring the intricate relationships between neuroscience and psychological processes since its inception in 1975. With both an ISSN of 0302-282X and an E-ISSN of 1423-0224, the journal is renowned for its rigorous peer-reviewed articles and significant contributions to the fields of Biological Psychiatry, Neuropsychology, and Physiological Psychology. Its impact is reflected in its esteemed Scopus rankings, standing out in the 92nd and 81st percentiles in their respective categories. With a commitment to advancing understanding in mental health and neurological science, NEUROPSYCHOBIOLOGY is classified in the Q3 and Q1 quartiles, making it a vital resource for researchers, clinicians, and students alike. Based in Switzerland, the journal embraces a holistic approach to psychological research, bridging gaps between theoretical frameworks and practical applications, thus promoting impactful advancements in the understanding of the human mind.
Explore the latest findings and theories with NEUROPSYCHOBIOLOGY, where your work can contribute to the evolving landscape of neuropsychological studies.

Neuropsychopharmacology Reports

Enhancing well-being with cutting-edge neuropsychopharmacology insights.
Publisher: WILEYISSN: Frequency: 4 issues/year

Neuropsychopharmacology Reports is a leading open-access journal published by WILEY, dedicated to advancing the fields of clinical psychology, pharmacology, psychiatry, and mental health. Established in 2018, the journal aims to disseminate high-quality research findings, critical reviews, and innovative methodologies that elucidate the complexities of neuropsychopharmacology in enhancing mental health outcomes. With an impressive impact indicated by its Q2 rankings in several categories including Clinical Psychology and Pharmacology (medical) as of 2023, Neuropsychopharmacology Reports stands out as a vital resource for researchers, professionals, and students keen on exploring the interplay between pharmacological interventions and psychological well-being. The journal’s open-access nature ensures that critical advancements in this rapidly evolving field are readily available to a global audience, fostering collaboration and discourse among scholars and practitioners alike. Building on its indexed status with Scopus, the journal is positioned as a noteworthy contributor to ongoing discussions and developments in psychiatry and medical pharmacology.